Precipio Inc (PRPO) USD0.001

Sell:$6.50Buy:$6.89$0.28 (4.23%)

Prices delayed by at least 15 minutes
Sell:$6.50
Buy:$6.89
Change:$0.28 (4.23%)
Prices delayed by at least 15 minutes
Sell:$6.50
Buy:$6.89
Change:$0.28 (4.23%)
Prices delayed by at least 15 minutes

Company Information

About this company

Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Company’s technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its technology enables testing to be completed in one rapid scanning process. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.

Key people

Ilan Danieli
Chief Executive Officer, Founder, Director
Matthew Gage
Chief Financial Officer
Ahmed Zaki Sabet
Chief Operations Officer
Ayman A. Mohamed
Chief Technology Officer
Richard Alvin Sandberg
Independent Chairman of the Board
Ronald A. Andrews
Independent Director
David S. Cohen
Independent Director
Jeffrey Cossman
Independent Director
Kathleen D. Laporte
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Technology
  • Industry
    Scientific & Technical Instr.
  • ISIN
    US74019L6020
  • Market cap
    $9.86m
  • Employees
    51
  • Shares in issue
    1.48m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.